
A new trial confirms that the drug selumetinib shrinks tumors in children suffering from neurofibromatosis type 1. The condition is characterized by changes in skin coloring and the growth of tumors along nerves in the skin, brain and other parts of the body. The tumors cause disfigurement, limitations on strength and range of motion, and… read on >